LumaCyte Launches Laser Force Cytology™ Academy after Training FDA Reviewers
July 30 2024 - 8:08AM
Business Wire
LumaCyte, a trailblazer in advanced label-free cellular
bioanalytical technology and instrumentation, proudly announces the
launch of the Laser Force Cytology™ Academy—an interactive library
of comprehensive training courses designed to deepen understanding
of LumaCyte’s transformative Laser Force Cytology™ (LFC™) optical
force technology. This new offering from LumaCyte aims to empower
scientists and biomanufacturers with the knowledge and skills
needed to leverage the power of LFC™ cellular analytics across
important process development and production laboratory
workflows.
Radiance®, LumaCyte’s flagship instrument powered by LFC™,
offers predictive cellular analytics for key bioprocess and
manufacturing applications. By providing label-free, quantitative
cell characterization, LFC™ enables scientists to monitor cellular
responses in near real-time without the need for antibodies or
genetic modification. These robust data insights ensure regulatory
compliance and maintain potency throughout critical development and
manufacturing processes.
This training initiative follows LumaCyte’s prestigious
invitation to train US FDA CBER cell and gene therapy reviewers on
LFC™. Such invitations are rarely extended to analytical tools
companies and highlights the growing interest in advanced
analytical solutions by regulators to support the increased need
for novel cell-based process analytical technologies (PAT).
"Receiving the FDA’s invitation to train 120 cell and gene
therapy and vaccine reviewers on Laser Force Cytology™ was an
incredible honor for LumaCyte,” says Renee Hart, LumaCyte,
President and Chief Business Officer. "With the CGT and vaccine
markets expected to grow dramatically through 2030, it’s essential
that we move beyond conventional approaches if we are to meet the
treatment demands ahead. Early integration of novel real-time
precision analytics will enhance both process and product
understanding and accelerate ever pressing development and
manufacturing timelines. The FDA’s proactive release of guidance
focused on cellular products manufacturing and potency underscores
the critical need for quantitative precision analytics to drive
improvements in both production quality and product consistency. We
are proud to support the vision of forward-thinking regulators and
contribute to the advancement of bioanalytics. Real-time data
insights illuminate complex development and production steps,
enabling rapid scaling, reducing manufacturing failures, and
ensuring successful patient treatments.”
The LumaCyte Academy comprises two modules, each designed for
different learning objectives. The first module includes an
introductory course on the fundamental principles of Laser Force
Cytology™, allowing the broader scientific community to explore its
capabilities and applications in cellular analysis and precision
bioanalytics. The second module, accessible only to Radiance®
users, provides a deeper dive into the instrument and technology,
empowering valued customers with the skills and expertise needed to
harness the full potential of Laser Force Cytology™ in their
laboratory workflows and processes. Additionally, Radiance® users
can now register for onsite training at LumaCyte headquarters,
where LumaCyte scientific experts and data analytics engineers will
provide users with hands-on training as part of the newly launched
Laser Force Cytology™ Academy.
LumaCyte is dedicated to bridging the gap between cutting-edge
technology and its adoption by biopharmaceutical developers and
manufacturers. Through fostering a network of expert users and
driving innovation, LumaCyte is advancing towards a future where
Laser Force Cytology™ is integral in delivering sophisticated
predictive analytics for the development and production of life
saving advanced therapies.
For more information and/or access to the LumaCyte Academy,
please visit www.lumacyte.com/academy.
About LumaCyte
LumaCyte, Inc. is an advanced research and bioanalytics
instrumentation company that produces label-free, single cell
analysis instrumentation where the use of antibody or genetic
labeling is not required for cellular analysis. This revolutionary
technology utilizes Laser Force Cytology™ (LFC™) to measure optical
and fluidic forces within a microfluidic channel, quantitatively
characterizing innate cellular responses of subtle phenotypic
changes based purely on the intrinsic biophysical and biochemical
properties of cells; which can be used to measure cellular changes
in response to their environment or treatment. The univariate and
multivariate nature of the data has enabled a host of big data
strategies and cloud computing capabilities that drive advanced
analytics, allowing a deeper understanding of cell based biological
systems. Applications of LumaCyte's label-free platform technology
include viral infectivity for vaccine development and
manufacturing, cell health, activation, transfection and
transduction analytics for cell and gene therapy development and
production monitoring, CAR T-cell immunotherapy, iPSC
differentiation, adventitious agent testing (AAT), infectious
disease, and pre-clinical drug discovery, in addition to multiple
applications across advanced therapy biomanufacturing for real-time
quality control.
Innovate. Discover. Transform.™
Visit www.lumacyte.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730795913/en/
Nicole Merli Director, Strategic Alliances & Communications
Phone: +1 434 322 3589 Email: nicole.merli@lumacyte.com